| Histology |
NSCLC, all subtypes
|
| Tumor stage |
Stage III - IV |
| NCT Id |
NCT06697197 |
| Host / recruiting site 1 |
Antoni van Leeuwenhoek
|
Enrollment |
Recruiting
|
| Therapy line |
Later line (≥2L)
|
| PD-L1 expression |
Negative: <1%Low: 1 - 49%High: ≥50%
|
| Design |
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
|
| Intervention |
DRUG: BMS-986482
Specified dose on specified days
DRUG: Nivolumab and rHuPH20
Specified dose on specified days
DRUG: Bevacizumab
Specified dose on specified days
|
| Key inclusion criteria |
- Participants must have recurrent or progressive disease during or after platinum doublet-based chemotherapy for advanced or metastatic disease, OR must have recurrent or progressive disease within 6 months after completing platinum-based chemotherapy
for local disease.
- Participants must have received anti-PD-(L)1 therapy, if eligible and available.
- Status for actionable mutations (eg, epidermal growth factor [EGFR], anaplastic lymphoma kinase [ALK], ROS oncogene 1 [ROS1], rearranged during transfection [RET], etc.) must be known (when testing is available as per country/region standard of
care practices); participants with actionable mutations must have received and progressed on, have been intolerant to, or not be a
candidate for standard tyrosine kinase inhibitors (as available per country/region standard-of-care practices).
|
| Key exclusion criteria |
- History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures.
- Untreated or symptomatic central nervous system (CNS) metastases. Participants are eligible if CNS metastases have been treated and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment). In addition, participants must have been either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg QD prednisone (or
equivalent) for at least 2 weeks prior to treatment assignment.
- History of medically significant thromboembolic events or bleeding diathesis within the past 6 months, eg, cerebrovascular accident (including transient ischemic attacks), pulmonary hemorrhage > 2 teaspoonfuls/24 hours or repeated pulmonary hemorrhage, or gastrointestinal hemorrhage requiring transfusion or procedural intervention.
|
| Contact information |
Log in voor de contactinformatie
|
